Zobrazeno 1 - 10
of 64 945
pro vyhledávání: ''
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Autor:
Lajos Pusztai, Gabriel N. Hortobagyi, Bryan T. Hennessy, Massimo Cristofanilli, Chafika Mazouni, Fabrice Andre, Attila Tordai, W. Fraser Symmans, Cornelia Liedtke, Marjorie C. Green, Ana M. Gonzalez-Angulo, Kenneth R. Hess, Jaime A. Mejia
Publikováno v:
Journal of Clinical Oncology. 41:1809-1815
PURPOSE Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. In this study, we compared response to neoadjuvant chemotherap
Autor:
Virginia Paton, Gracie Lieberman, Melody A. Cobleigh, Debasish Tripathy, Nicholas J. Robert, Charles L. Vogel, Louis Fehrenbacher, Janet M. Wolter, Steven Shak, Susy Scholl, Dennis J. Slamon
Publikováno v:
Journal of Clinical Oncology. 41:1501-1510
PURPOSE Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody as a single agent was evalu
Publikováno v:
Journal of Clinical Oncology. 41:1331-1338
PURPOSE Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional ligand-binding assay (LBA). The purpose
Autor:
Elizabeth Bancroft, Chee Goh, Elizabeth Page, Zsofia Kote-Jarai, Elena Castro, Christos Mikropoulos, Edward J. Saunders, Nandita M. deSouza, David E. Neal, Stephen Hazell, Antonis C. Antoniou, Natalie Taylor, Pardeep Kumar, Nigel Borley, Rosalind A. Eeles, Freddie C. Hamdy, Sibel Saya, Naomi Livni, Diana Keating, Tokhir Dadaev
Publikováno v:
The Oncologist
A better assessment of prostate cancer (PrCa) risk is needed to improve screening. The PROFILE pilot study explored the feasibility of single nucleotide polymorphism profiling in men with a family history (FH) of PrCa to investigate the probability o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::530db08f3b0071b7ef326b41d3c41f1a
https://ora.ox.ac.uk/objects/uuid:5985ee3f-ba82-44cd-9894-a0e866e55da9
https://ora.ox.ac.uk/objects/uuid:5985ee3f-ba82-44cd-9894-a0e866e55da9
Autor:
Qing Liu, Emily M. Ko, Katherine Hicks-Courant, Colleen M. Brensinger, Marilyn M. Schapira, Genevieve P. Kanter
Publikováno v:
International Journal of Gynecologic Cancer. 32:695-703
12032 Background: The impact of primary oncologist specialty, medical oncology (MO) versus gynecologic oncology (GO), on intensity of care at the end of life (EOL) in elderly patients with gynecologic cancer is unclear. Methods: This retrospective co
Autor:
Vieri Scotti, Beatrice Fantechi, Francesca Mazzoni, I. Stasi, Irene Pecora, Carmelo Tibaldi, Enrico Vasile, Chiara Caparello, Editta Baldini, Marianna Turrini, Lorenzo Antonuzzo, Francesca Federici, Andrea Camerini, Giulia Meoni, Daniele Pozzessere, Diana Giannarelli, Virginia Rossi, L.P. Ciccone
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 22:1278-1285
Background: In advanced non-small-cell lung cancer, without activating mutations and with PD-L1≥50%, Pembrolizumab monotherapy is the therapeutic standard in Europe. Objective: To evaluate retrospectively the safety and efficacy of this drug and to
Publikováno v:
Breast Cancer Res Treat
PURPOSE: Aging associated with progressive declines in physical function is well-known; however, little is known about the trajectories of physical function before and after breast cancer diagnosis. The current study examined the trajectories in obje
Autor:
Paul Mitchell, G Rivalland, Hui Yu, Fred R. Hirsch, R. Mosher, L Churilov, K Asadi, Christopher J. Rivard, S Heynemann
Publikováno v:
Clinical Lung Cancer. 23:e90-e98
Background NaPi2b is a multi-transmembrane sodium-dependent phosphate transporter expressed at normal levels in several organs, including lung. High expression levels have been reported in various tumours including breast, thyroid, ovarian and non-sm